E
Viracta Therapeutics, Inc.
VIRX
$0.022
-$0.0048-17.91%
E
Sell
8/19/2024Downgrade
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from D- on 8/19/2024 due to a significant decline in the solvency index, growth index and volatility index. Operating cash flow declined 25.2% from -$7.85M to -$9.83M, the quick ratio declined from 1.31 to 1.05, and earnings per share declined from -$0.2325 to -$0.2495.
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from D- on 8/19/2024 due to a significant decline in the solvency index, growth index and volatility index. Operating cash flow declined 25.2% from -$7.85M to -$9.83M, the quick ratio declined from 1.31 to 1.05, and earnings per share declined from -$0.2325 to -$0.2495.
D
Sell
8/16/2024Upgraded
Viracta Therapeutics, Inc. (VIRX) was upgraded to D- from E+ on 8/16/2024 due to an increase in the valuation index and volatility index.
Viracta Therapeutics, Inc. (VIRX) was upgraded to D- from E+ on 8/16/2024 due to an increase in the valuation index and volatility index.
E
Sell
6/6/2024Downgrade
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from D- on 6/6/2024 due to a decline in the valuation index, volatility index and solvency index. Debt to equity increased from 1.99 to 3.35, and the quick ratio declined from 1.41 to 1.31.
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from D- on 6/6/2024 due to a decline in the valuation index, volatility index and solvency index. Debt to equity increased from 1.99 to 3.35, and the quick ratio declined from 1.41 to 1.31.
D
Sell
5/21/2024Upgraded
Viracta Therapeutics, Inc. (VIRX) was upgraded to D- from E+ on 5/21/2024 due to an increase in the volatility index and total return index.
Viracta Therapeutics, Inc. (VIRX) was upgraded to D- from E+ on 5/21/2024 due to an increase in the volatility index and total return index.
E
Sell
5/3/2024Downgrade
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from D- on 5/3/2024 due to a decline in the volatility index.
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from D- on 5/3/2024 due to a decline in the volatility index.
D
Sell
4/18/2024Upgraded
Viracta Therapeutics, Inc. (VIRX) was upgraded to D- from E+ on 4/18/2024 due to an increase in the volatility index.
Viracta Therapeutics, Inc. (VIRX) was upgraded to D- from E+ on 4/18/2024 due to an increase in the volatility index.
E
Sell
8/30/2023Downgrade
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from D- on 8/30/2023 due to a decline in the volatility index.
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from D- on 8/30/2023 due to a decline in the volatility index.
D
Sell
8/15/2023Upgraded
Viracta Therapeutics, Inc. (VIRX) was upgraded to D- from E+ on 8/15/2023 due to an increase in the volatility index, growth index and total return index. Operating cash flow increased 29.54% from -$11.34M to -$7.99M.
Viracta Therapeutics, Inc. (VIRX) was upgraded to D- from E+ on 8/15/2023 due to an increase in the volatility index, growth index and total return index. Operating cash flow increased 29.54% from -$11.34M to -$7.99M.
E
Sell
3/14/2023Downgrade
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from D- on 03/14/2023.
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/23/2023Upgraded
Viracta Therapeutics, Inc. (VIRX) was upgraded to D- from E+ on 02/23/2023.
Viracta Therapeutics, Inc. (VIRX) was upgraded to D- from E+ on 02/23/2023.
E
Sell
2/8/2023Downgrade
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
D
Sell
11/17/2022Downgrade
Viracta Therapeutics, Inc. (VIRX) was downgraded to D- from D on 11/17/2022 due to a decline in the growth index, volatility index and total return index. EBIT declined 72.09% from -$10.51M to -$18.08M, and earnings per share declined from -$0.2814 to -$0.4706.
Viracta Therapeutics, Inc. (VIRX) was downgraded to D- from D on 11/17/2022 due to a decline in the growth index, volatility index and total return index. EBIT declined 72.09% from -$10.51M to -$18.08M, and earnings per share declined from -$0.2814 to -$0.4706.
D
Sell
9/1/2022Upgraded
Viracta Therapeutics, Inc. (VIRX) was upgraded to D from D- on 9/1/2022 due to an increase in the total return index and volatility index.
Viracta Therapeutics, Inc. (VIRX) was upgraded to D from D- on 9/1/2022 due to an increase in the total return index and volatility index.
D
Sell
8/17/2022Downgrade
Viracta Therapeutics, Inc. (VIRX) was downgraded to D- from D on 8/17/2022 due to a decline in the growth index, volatility index and solvency index. The quick ratio declined from 11.87 to 11.51, EBIT declined 0.7% from -$10.43M to -$10.51M, and earnings per share declined from -$0.281 to -$0.2814.
Viracta Therapeutics, Inc. (VIRX) was downgraded to D- from D on 8/17/2022 due to a decline in the growth index, volatility index and solvency index. The quick ratio declined from 11.87 to 11.51, EBIT declined 0.7% from -$10.43M to -$10.51M, and earnings per share declined from -$0.281 to -$0.2814.
D
Sell
8/4/2022Upgraded
Viracta Therapeutics, Inc. (VIRX) was upgraded to D from D- on 8/4/2022 due to an increase in the volatility index and total return index.
Viracta Therapeutics, Inc. (VIRX) was upgraded to D from D- on 8/4/2022 due to an increase in the volatility index and total return index.
D
Sell
7/20/2022Downgrade
Viracta Therapeutics, Inc. (VIRX) was downgraded to D- from D on 7/20/2022 due to a decline in the volatility index and valuation index.
Viracta Therapeutics, Inc. (VIRX) was downgraded to D- from D on 7/20/2022 due to a decline in the volatility index and valuation index.
D
Sell
6/28/2022Upgraded
Viracta Therapeutics, Inc. (VIRX) was upgraded to D from D- on 6/28/2022 due to an increase in the volatility index and total return index.
Viracta Therapeutics, Inc. (VIRX) was upgraded to D from D- on 6/28/2022 due to an increase in the volatility index and total return index.
D
Sell
6/13/2022Downgrade
Viracta Therapeutics, Inc. (VIRX) was downgraded to D- from D on 6/13/2022 due to a decline in the volatility index and valuation index.
Viracta Therapeutics, Inc. (VIRX) was downgraded to D- from D on 6/13/2022 due to a decline in the volatility index and valuation index.
D
Sell
5/20/2022Upgraded
Viracta Therapeutics, Inc. (VIRX) was upgraded to D from E+ on 5/20/2022 due to an increase in the volatility index and total return index.
Viracta Therapeutics, Inc. (VIRX) was upgraded to D from E+ on 5/20/2022 due to an increase in the volatility index and total return index.
E
Sell
5/13/2022Downgrade
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from D- on 5/13/2022 due to a decline in the solvency index, volatility index and valuation index. Debt to equity increased from 0.06 to 0.07.
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from D- on 5/13/2022 due to a decline in the solvency index, volatility index and valuation index. Debt to equity increased from 0.06 to 0.07.
D
Sell
5/5/2022Upgraded
Viracta Therapeutics, Inc. (VIRX) was upgraded to D- from E+ on 05/05/2022.
Viracta Therapeutics, Inc. (VIRX) was upgraded to D- from E+ on 05/05/2022.
E
Sell
4/20/2022Downgrade
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from D- on 04/20/2022.
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from D- on 04/20/2022.
D
Sell
3/21/2022Upgraded
Viracta Therapeutics, Inc. (VIRX) was upgraded to D- from E+ on 3/21/2022 due to a large increase in the growth index, volatility index and solvency index. Earnings per share increased from -$0.3993 to -$0.3058, and operating cash flow increased 5.09% from -$7.6M to -$7.21M.
Viracta Therapeutics, Inc. (VIRX) was upgraded to D- from E+ on 3/21/2022 due to a large increase in the growth index, volatility index and solvency index. Earnings per share increased from -$0.3993 to -$0.3058, and operating cash flow increased 5.09% from -$7.6M to -$7.21M.
E
Sell
12/28/2021Downgrade
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from D- on 12/28/2021 due to a decline in the volatility index and total return index.
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from D- on 12/28/2021 due to a decline in the volatility index and total return index.
D
Sell
12/10/2021Upgraded
Viracta Therapeutics, Inc. (VIRX) was upgraded to D- from E+ on 12/10/2021 due to an increase in the volatility index.
Viracta Therapeutics, Inc. (VIRX) was upgraded to D- from E+ on 12/10/2021 due to an increase in the volatility index.
E
Sell
11/24/2021Downgrade
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from D- on 11/24/2021 due to a noticeable decline in the growth index, total return index and efficiency index. Net income declined 62.64% from -$9.17M to -$14.91M, earnings per share declined from -$0.2464 to -$0.3993, and EBIT declined 15.91% from -$9.32M to -$10.8M.
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from D- on 11/24/2021 due to a noticeable decline in the growth index, total return index and efficiency index. Net income declined 62.64% from -$9.17M to -$14.91M, earnings per share declined from -$0.2464 to -$0.3993, and EBIT declined 15.91% from -$9.32M to -$10.8M.
D
Sell
11/3/2021Upgraded
Viracta Therapeutics, Inc. (VIRX) was upgraded to D- from E on 11/3/2021 due to an increase in the valuation index.
Viracta Therapeutics, Inc. (VIRX) was upgraded to D- from E on 11/3/2021 due to an increase in the valuation index.
E
Sell
10/8/2021Downgrade
Viracta Therapeutics, Inc. (VIRX) was downgraded to E from E+ on 10/8/2021 due to a decline in the volatility index and total return index.
Viracta Therapeutics, Inc. (VIRX) was downgraded to E from E+ on 10/8/2021 due to a decline in the volatility index and total return index.
E
Sell
9/23/2021Upgraded
Viracta Therapeutics, Inc. (VIRX) was upgraded to E+ from E on 9/23/2021 due to an increase in the volatility index.
Viracta Therapeutics, Inc. (VIRX) was upgraded to E+ from E on 9/23/2021 due to an increase in the volatility index.
E
Sell
9/8/2021Downgrade
Viracta Therapeutics, Inc. (VIRX) was downgraded to E from E+ on 9/8/2021 due to a decline in the volatility index and total return index.
Viracta Therapeutics, Inc. (VIRX) was downgraded to E from E+ on 9/8/2021 due to a decline in the volatility index and total return index.
E
Sell
8/18/2021None
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from U on 08/18/2021.
Viracta Therapeutics, Inc. (VIRX) was downgraded to E+ from U on 08/18/2021.
OTC PK
04/04/2025 12:48PM Eastern
Quotes delayed
